Jump to main content
Jump to site search

Issue 10, 2016
Previous Article Next Article

From haystack to needle: finding value with DNA encoded library technology at GSK

Author affiliations

Abstract

DNA encoded library technology (ELT) provides access to broad chemical diversity through affinity selection. As an early adopter, GlaxoSmithKline enabled the development of ELT from proof of concept to full fledged contributor to the small molecule therapeutic pipeline. Unique benefits of the GSK incubation include uptake of large numbers of building blocks and privileged scaffolds, guidance on library design, and opportunities to add value beyond lead discovery. Soluble epoxide hydrolase and RIP1 kinase represent two case studies of ELT hits that have advanced into clinical studies. ELT also shows promise as a strategy to forecast target tractability. As an emerging technology, it benefits from incubation at the interface of industry and academia.

Graphical abstract: From haystack to needle: finding value with DNA encoded library technology at GSK

Back to tab navigation

Publication details

The article was received on 17 Jun 2016, accepted on 13 Jul 2016 and first published on 25 Jul 2016


Article type: Review Article
DOI: 10.1039/C6MD00341A
Med. Chem. Commun., 2016,7, 1898-1909

  •   Request permissions

    From haystack to needle: finding value with DNA encoded library technology at GSK

    C. C. Arico-Muendel, Med. Chem. Commun., 2016, 7, 1898
    DOI: 10.1039/C6MD00341A

Search articles by author

Spotlight

Advertisements